Elizabeth S. Miller

发表

Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series

E. Lipp, H. Friedman, J. Kirkpatrick, 2020, Journal of Neuro-Oncology.

Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.

E. Lipp, H. Friedman, D. Reardon, 2015, The oncologist.

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

E. Lipp, H. Friedman, D. Reardon, 2018, Journal of Neuro-Oncology.

A cross sectional analysis from a single institution’s experience of psychosocial distress and health-related quality of life in the primary brain tumor population

S. Keir, E. Lipp, H. Friedman, 2017, Journal of Neuro-Oncology.

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial

E. Lipp, H. Friedman, A. Desjardins, 2021, Supportive Care in Cancer.

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide

E. Lipp, H. Friedman, A. Desjardins, 2019, Supportive Care in Cancer.

Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.

E. Lipp, H. Friedman, A. Desjardins, 2019, Complementary therapies in clinical practice.

Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).

E. Lipp, H. Friedman, A. Desjardins, 2012 .

Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.

E. Lipp, H. Friedman, A. Desjardins, 2021, Neuro-oncology practice.